



# EGA VISION



The European Generic medicines Association (EGA) is at the heart of Europe's medicines industry and is essential to EU Public Health

## • PATIENTS

1



- Patient access to medicines significantly increases when generic medicines companies enter the market
- 52% of all medicines taken by patients in Europe are generic medicines

## • QUALITY

2



- Generic medicines are developed according to stringent regulatory requirements. Manufacturing is also highly regulated
- We advocate the enforcement of the highest quality standards in all countries around the world – as you would find in the EU

## • VALUE

3



- Average daily cost of a generic medicine is just 25 Eurocents
- Generic and biosimilar medicines save 35 bn euros per year
- This is an incredible service to patient health and budget control
- The EU 28 must stimulate the healthcare systems to use generics

## • SUSTAINABILITY

4



- 75% of generic medicines consumed are produced in the EU
- The EU has 1000 companies with 150,000 employees
- Generic medicines companies are innovating: 7% R&D investment
- We must support this industry to grow and lead in the world through allowing manufacture for export during EU SPC

## • PARTNERSHIP

5



- The European Generic medicines Association (EGA) will work in close collaboration with the EU Institutions, governments, patients groups, healthcare professional groups and other stakeholders to enhance EU public health